Aflac (NYSE: AFL) Q1 2026: Revenue Beat, EPS Misses Consensus by 2.5%

Aflac Incorporated (NYSE: AFL) reported Q1 CY2026 results on April 29, 2026 — confirmed by an SEC EDGAR 8-K filing under Item 2.02 (Results of Operations) — with revenue coming in ahead of Wall Street expectations while non-GAAP EPS of $1.75 missed the analyst consensus by 2.5%. Shares edged marginally lower, closing at $116.21, down $0.08 (0.07%) on the day, as the mixed report left investors weighing top-line resilience against profitability pressure.

Q1 2026 At a Glance

• Revenue: $4.35 billion, beating Wall Street estimates but flat year-over-year
• Non-GAAP EPS: $1.75, approximately 2.5% below the analyst consensus
• Trailing P/E: 17.1x | Forward P/E: 15.1x
• Net margin: 21.2% | Operating margin: 33.6%
• Gross margin: 46.6%
• Revenue growth (YoY): -9.9% | Net income growth (YoY): -22.9%
• Market capitalisation: $59.9 billion
• 52-week range: $96.95 – $119.32

What Drove the Results

The flat top-line performance and year-over-year revenue decline of -9.9% reflect ongoing headwinds in Aflac's core supplemental insurance business, which operates in both the U.S. and Japan. The -22.9% decline in net income growth year-over-year signals that cost or claims dynamics are weighing more heavily on profitability than revenue trends alone can explain, though the company has not provided detailed segment-level guidance in the data available.

Despite the profit shortfall, Aflac's operating margin of 33.6% and net margin of 21.2% remain structurally solid for the supplemental insurance sector. The company's forward P/E of 15.1x — a meaningful discount to its trailing multiple of 17.1x — suggests the market is pricing in some degree of earnings recovery ahead, though near-term results have not yet supported that optimism.

Wall Street View

Analyst sentiment on (NYSE: AFL) has shifted noticeably more cautious over recent months. As of April 2026, the consensus stands at 1 Strong Buy, 2 Buy, 11 Hold, 7 Sell, and 1 Strong Sell — a materially more bearish distribution compared to the March 2026 reading of 1 Strong Buy, 2 Buy, and 10 Hold, which carried no sell-side negative ratings at all. The addition of 8 Sell or Strong Sell ratings in a single month is a meaningful shift in institutional sentiment that investors should monitor closely.

Investor Takeaway

Aflac's Q1 2026 report presents a mixed picture: revenue held above expectations, but the 2.5% EPS miss and double-digit declines in both revenue and net income on a year-over-year basis underscore real near-term pressure on the business. The sharp deterioration in analyst recommendations — from a broadly constructive stance in March to a notably divided one in April — suggests Wall Street is reassessing the near-term trajectory. Investors may find some comfort in the company's durable operating margins and a forward P/E that implies modest earnings improvement, but the current fundamental backdrop warrants a measured approach.